Biotech Values

[genisi]

Savella

...different people respond to different drugs,...

Further, FMS is a very complexed disease and symptoms tend to vary from patient to patient. Also, patient are very willing to try new meds and the rate of switching is high.
Savella is competing directly with Cymbalta, which is the only other approved SNRI in FMS and I think docs view them as undifferentiated here. This might be a problem for Savella when be Cymbalta generics will be available.

Blood pressure increases in the range of 2-2.5mmHg were seen with Cymbalta in clinical trials, so similar to palpitations, tachycardia, and hypertension these are consistent with NSRI mechanism. Moreover, label warnings for hypertension and heart-rate elevations are standard.